Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.53 |
| ▸ | KDR | P35968 | 7/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | GRK5 | P34947 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13755218 | 1.00 | CHEK1 (0.53) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL13755179 | 0.90 | KDR (0.59) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL2114173 | 0.90 | KDR (0.59) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL2115628 | 0.86 | KDR (0.55) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL13755190 | 0.86 | KDR (0.55) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL13755215 | 0.83 | KDR (0.72) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL31672546 | 0.83 | KDR (0.72) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL2113981 | 0.83 | KDR (0.72) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL31672397 | 0.82 | KDR (0.62) | CHEK1KDRPRKAA1PRKAA2PDGFRB | |
| SCHEMBL2117421 | 0.82 | KDR (0.62) | CHEK1KDRPRKAA1PRKAA2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | CHEK1 716/4885KDR 395/4885PRKAA1 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.